.Attributes Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint requires addition of individuals with MASLD and dimension of liver outcomes in cardio-- renal-- metabolic tests, when records suggest mechanistically conceivable benefits and also clinical safety and security-- and describes factors to consider for trial design and also regulatory commendation.